Atlas FDA

Versant HCV Genotype 2.0 Assay (LiPA)

FDA premarket approval P160016/S004 · decided 2019-09-20

Approval details

PMA number
P160016
Supplement
S004
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
Versant HCV Genotype 2.0 Assay (LiPA)
Generic name
Assay, genotyping, hepatitis c virus
Applicant
Fujirebio Europe N.V.
Date received
2019-07-25
Decision date
2019-09-20
Days to decision
57 days
Decision code
OK30
Product code
OBF
Advisory committee
Microbiology
Expedited review
No
Location
Gent
Statement
Change plastic resin used in non-critical component vials.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.